Comparing total health care costs and treatment patterns of HIV patients in a managed care setting

被引:14
作者
Purdum, AG
Johnson, KA
Globe, DR
机构
[1] Univ So Calif, Sch Pharm, Dept Pharm, Los Angeles, CA 90033 USA
[2] Univ So Calif, Sch Pharm, Dept Pharmaceut Econ & Policy, Los Angeles, CA 90033 USA
[3] Genentech Inc, San Francisco, CA 94080 USA
来源
AIDS CARE-PSYCHOLOGICAL AND SOCIO-MEDICAL ASPECTS OF AIDS/HIV | 2004年 / 16卷 / 06期
关键词
D O I
10.1080/09540120412331269602
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
The objective of this study was to investigate total health care costs and time to occurrence of hospitalization in HIV-infected patients treated according to the 1998 DHHS guidelines in a managed care setting. The study also investigated which patients do not receive guideline treatment. We used a retrospective cross-sectional study design using medical and pharmacy claims data. Data from 1,791 HIV-infected patients using antiretroviral agents between 1 February 1998 and 31 July 1999, including demographic characteristics, medication guideline use, medication adherence and cost of care, were examined. Factors associated with total health care costs and time-to-inpatient admission ( as a proxy for patient outcomes) were assessed. Patients receiving guideline ( HAART) therapy (55%) had higher prescription and total health care costs but lower medical costs. Patients not receiving treatment according to guidelines were more likely to be female, older, have comorbidities, lower medication adherence and no AIDs-defining illness. Treatment with HAART guidelines was associated with longer time-to-inpatient admission controlling for other factors. In a short-term cross-sectional analysis, patients treated with HAART guidelines had better outcomes based on time-to-inpatient admission but higher prescription and total health care costs. Some patients are at risk for not receiving care according to national treatment guidelines and may be targeted for intervention programmes.
引用
收藏
页码:767 / 780
页数:14
相关论文
共 31 条
[1]   Average annual drug cost and its determinants in a population based cohort of HIV-positive adult men and women [J].
Anis, AH ;
Hogg, RS ;
Yip, B ;
Wang, XH ;
Montaner, JSG ;
O'Shaughnessy, MV ;
Schechter, MT .
PHARMACOECONOMICS, 1998, 13 (03) :327-336
[2]   Modelling the potential economic impact of viral load-driven triple drug combination antiretroviral therapy [J].
Anis, AH ;
Hogg, RS ;
Wang, XH ;
Yip, B ;
Palepu, A ;
Montaner, JSG ;
O'Shaughnessy, MV ;
Schechter, MT .
PHARMACOECONOMICS, 1998, 13 (06) :697-705
[3]  
[Anonymous], 1998, MMWR Recomm Rep, V47, P1
[4]  
BESCH CL, 1997, 4 NAT C RETR OPP INF
[5]   Apoprotein C-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors:: Association with the development of lipodystrophy [J].
Bonnet, E ;
Ruidavets, JB ;
Tuech, J ;
Ferrières, J ;
Collet, X ;
Fauvel, J ;
Massip, P ;
Perret, B .
JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2001, 86 (01) :296-302
[6]   The care of HIV-infected adults in the United States [J].
Bozzette, SA ;
Berry, SH ;
Duan, NJ ;
Frankel, MR ;
Leibowitz, AA ;
Lefkowitz, D ;
Emmons, CA ;
Senterfitt, JW ;
Berk, ML ;
Morton, SC ;
Shapiro, MF .
NEW ENGLAND JOURNAL OF MEDICINE, 1998, 339 (26) :1897-1904
[7]  
*CDCP, 1993, MORBIDITY MORTALITY, V41
[8]  
*CDCP, 1999, HIV AIDS SURVEILLANC, V11, P1
[9]  
Centers for Disease Control and Prevention, 1997, HIV AIDS SURVEILLANC, V9, P1
[10]  
Centers for Disease Control and Prevention, 2000, HIV AIDS SURVEILLANC, V12, P1